Background: Dengue fever (DF) is a frequently imported arthropod-borne infection in the United Kingdom but its broad range of clinical presentations makes it potentially unrecognized by clinicians. Methods: We conducted a 6-year retrospective case note review of laboratory confirmed DF patients in East London in the period from 1 January 2010 through 31 December 2015. Epidemiological, clinical and laboratory features of imported DF were described. Risk factors associated with viraemic DF presentations were assessed. Results: Forty-four patients (4 from primary care clinics and 40 from three acute hospitals) were confirmed to have DF through RNA and/or IgM detection. In total, 86.4% (38/44) had primary infection compared to 13.6% (6/44) with secondary infection. Viraemic DF presentations accounted for 59.1% (26/44) of cases. The median age was 34 years . Most patients were males (68.2%, 30/44) and of non-white ethnicity (81.8%, 36/44). South Asia was the most frequent travel destination (52.3%, 23/44) followed by Southeast Asia (20.5%, 9/44). July-September was the peak season of presentation (43.2%, 19/44). The median interval between arrival in the UK and laboratory testing was 7 days (IQR 4-13). Arriving from abroad 7 days before molecular testing (age-adjusted odds ratios [OR] 16.98, 95% CI 2.43-118.75, P ¼ 0.004) and travel to South or Southeast Asia regions (age-adjusted OR 4.41, 95% CI 1.07-18.21, P ¼ 0.040) were associated with detectable viraemia at presentation. Only one DF patient met the WHO severity criteria. HIV serostatus was determined in 61.4% (27/44) of cases. Conclusion: Clinicians need to improve DF recognition as well as rates of HIV testing in tropical travellers. Region of travel and time since arrival from DF endemic settings may help clinicians optimize requests for molecular testing. Further research on the clinical and public health aspects of imported DF is needed.
Introduction
Dengue fever (DF) is the most common imported arthropodborne viral infection and is the leading cause of fever in tropical travellers, with the exception of those arriving from SubSaharan Africa. 1, 2 Unprecedented increase in international travel over the past decades and subsequent importation of viraemic DF cases to Europe, 3 climate change leading to establishment of Aedes albopictus in continental Europe as well as the re-emergence of Ae. aegypti, [4] [5] [6] and autochthonous transmission of DF in several European countries, 7, 8 including a large scale outbreak complicated by exportation of infection to other parts of the continent, 9,10 are major causes for concern about the situation of DF in Europe. Although DF has been shown to be the 4th commonest cause for hospital admissions among travellers in the United Kingdom (UK), 11 DF is often missed or misclassified by clinicians.
Furthermore, access to DF diagnostics is limited to specialist centres and the vast majority of requests for DF investigations have been made by infectious diseases specialists. 11, 12 This study aims to describe the epidemiological, clinical, and laboratory features of imported DF in East London over a 6-year period. We also explored the risk factors associated with viraemic clinical presentations of DF. We hypothesised that the burden of DF is underestimated in our local population.
Materials and Methods

Setting
Barts Health NHS Trust serves a large ethnically diverse population of 2.5 million people living in East London in the boroughs of Tower Hamlets, Newham, and Waltham Forest. It runs three acute hospitals (Royal London Hospital, Newham University Hospital, Whipps Cross University Hospital) and the annual attendance episodes of its emergency departments is approximately 325 000 per year.
Patients
We retrospectively searched our electronic pathology database for all laboratory requests for DF serology originating from any of our hospitals or any primary care clinic within our catchment area in the period from 1st January 2010 to 31st December 2015. We then identified all laboratory confirmed cases of DF and reviewed their clinical records.
Diagnostics Methods
Blood samples for DF testing were referred to the Rare and Imported Pathogens Laboratory (RIPL) [Public Health England, Porton Down, United Kingdom] where further serological and molecular testing based on the region of travel and the presenting symptoms was performed. 13 At RIPL, detection of dengue virus (DENV) IgM and IgG antibodies were performed using commercial ELISA test kits (Panbio V R Dengue Duo IgM Capture and IgG Capture ELISA, Alere International Limited, Ireland). For IgG and IgM results, an optical density/cut-off ratio of 0.9-1.1 was interpreted as indeterminate whereas that of >1.1 was considered as detectable. An in-house qualitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay (Public Health England, Porton Down, UK) was used for DENV ribonucleic acid (RNA) detection.
Results of our local 4th generation screening assay for the human immunodeficiency virus (HIV) [The ARCHITECT HIV Ag/Ab Combo assay, Abbott, USA] were reviewed to check whether the HIV serostatus of patients with DF was determined at the time of presentation as UK guidelines recommend HIV testing for febrile tropical travellers. 14 
Case Definitions
We followed standard WHO definitions for primary and secondary dengue infections. 15 Logistic regression was used to assess the association between viraemic clinical presentation of DF (defined as detection of DENV RNA in a blood sample) and age, sex, ethnicity, region of travel, season of presentation and the length of time between arriving in the UK and blood sampling for DF testing. Crude and age-adjusted odds ratios (ORs) together with 95% confidence intervals (CIs) were calculated.
Ethics Statement
This study was registered as a quality improvement project with the clinical effectiveness unit at Barts Health NHS Trust (registration no. 6756). This work involved secondary use of nonidentifiable patient information that was previously collected in the course of routine care. Data were anonymized prior to analysis.
Results
General Characteristics
In total, 168 laboratory requests were made for dengue serology over the 6-year period of the study. In total, 44 patients (4 were referred by primary care physicians and 40 by secondary care physicians) were found to have molecular or serological evidence of DF: 86.4% (38/44) had primary DENV infection while 13.6% (6/44) secondary DENV infection. The total number of reported DF cases increased from 6 cases during 2010-2012 to 38 during 2013-2015. Table 1 presents demographic and clinical features of patients with DF. Patients were aged 2-87 years (median 34; IQR 25-43). Patients aged <15 years accounted for 9.1% (4/44) while those aged >65 years accounted for 4.5% (2/44). Males accounted for 68.2% (30/44) of patients. Overall, the majority of patients were of non-white ethnicity (81.8%; 36/44). Patients from Asian background were the most affected group by imported DF (61.4%; 27/44).
Region of Travel
South Asia was the most frequent travel destination (52.3%, 23/ 44), with 12 patients from India, nine from Bangladesh, and one patient from Pakistan and Sri Lanka. Southeast Asia was the second commonest destination (20.5%; 9/44) with four patients from Indonesia, two from Thailand, and one patient each from Malaysia, Philippines and Singapore. Countries visited in the Caribbean region included Barbados, Cuba, Jamaica and St Lucia. Travel to South America was limited to Brazil and Colombia while travel to Africa was restricted to Guinea and Somalia.
Season of Presentation
July-September was the peak quarter for clinical presentation with DF (43.2%, 19/44). In total, 61.4% (27/44) of patients with DF presented during April-September season compared to 38.6% (17/44) during October-March. Although most patients with viraemic DF presented during October-March (70.6%, 12/17) compared to April-September (51.9%, 14/27), this difference was not statistically significant (v 2 ¼1.51, 1 degree of freedom, P ¼ 0.218). Figure 1 shows the seasonal distribution of DF cases as well as the proportion of cases with detectable viraemia at presentation.
Clinical and Laboratory Features
Information on the length of time between arrival in the UK and blood sampling for DF testing was available for 24 patients (median 7 days; IQR 4-13). The median length of time between arrival in the UK for DF patients with detectable DENV RNA at presentation was 6 days (IQR 3.5-7) compared to 16.5 days (IQR 9-20) for those with undetectable DENV RNA.
Most frequently reported symptoms at presentation were fever (95.5%; 42/44), muscle or joint pain (27.3%; 12/44), rash (22.7%; 10/44), diarrhoea (22.7%;/10/44), vomiting (22.7%; 10/44), headache (18.2%; 8/44) and bleeding (11.4%;5/44: four patients had epistaxis and one patient had oral mucosal bleeding).
Information on the duration of symptoms was available for 28 DF patients (median 5 days; IQR 4-9). The median duration 
Age (years) of symptoms was 4 days (IQR 4-5) for patients with detectable DENV RNA at presentation compared to 12 days (IQR 6-18) for those with undetectable DENV RNA. HIV serostatus was determined in 61.4% (27/44) of DF patients, and all of them tested negative. None of the 10 women of child-bearing age had their pregnancy status documented.
Viraemic DF presentation accounted for 59.1% (26/44) of all DF cases. Of these, 20 patients had primary DENV infection and 6 patients had secondary DENV infection (Table 1 ). In total, 9.1% (4/44) of patients had undetectable IgM/IgG antibodies but their dengue virus RNA was detectable by RT-PCR. Three patients (one with primary dengue infection and two with re-infection) had indeterminate IgM antibody results but their corresponding RT-PCR results were positive (Table 1) . 
Complications and Clinical Outcomes
One male patient aged 3 years old with primary DENV infection met the WHO severity criteria. 15 This was evidenced by severe epistaxis requiring platelets transfusion, plasma leakage (bilateral pleural effusions and ascites), and probable haemophagocytic lymphohistiocytosis syndrome for which he received steroids with good effect (bone marrow examination was not feasible due to concerns about bleeding tendency). Information on clinical outcomes was available on 43 patients, all of whom were discharged alive. In total, 3 tropical coinfections were reported: Plasmodium vivax was confirmed in an Asian male arriving from India; P. falciparum was confirmed in a female arriving from Guinea; and rickettsial infection as evidenced by detectable IgM antibodies for epidemic typhus and spotted fever was considered in a female returning from Barbados. Table 2 . Laboratory characteristics of patients presenting with imported dengue fever (n ¼ 44) in East London, January 2010-December 2015
Discussion
We presented 6-year data on the clinical and epidemiological features of imported DF in East London. In our setting, DF patients were typically young males of non-white ethnicity with recent travel history to South or Southeast Asia. Although we were not able to capture the purpose of travel in this study, it is likely that visiting friends and relatives (VFR) in countries of origin was common given the ethnicity and travel destinations of our DF patients. This is consistent with the fact that DF cases in the UK have mainly been documented in VFRs compared to holidaymakers and workers in continental Europe.
11,16
The vast majority of our patients had primary dengue infections indicating lack of prior immunity. This is interesting because we expected our ethnically diverse population to have some background immunity and therefore generate more secondary than primary infections.
Time since arrival from abroad might be a better marker than duration of symptoms as the former takes into account the maximum incubation period for DF and is less prone to recall bias as the dates could potentially be verified by checking relevant travel documents. We found that a shorter time interval of 7 days between arrival from the endemic area and DF testing was associated with the detection of DENV RNA by RT-PCR, and this finding may help clinicians optimize referrals for RT-PCR testing. Furthermore, the average duration of DF viraemia in returning travellers (9 days) was found to be longer than that of people living in endemic settings (5-7 days). [17] [18] [19] This observation is most likely explained by predominance of primary infections in travel-associated DF and it may also facilitate rational use of molecular diagnostics. The 6-fold rise in our DF cases between 2010-12 and 2013-15 has been mirrored nationally by 36% annual increase between 2009 and 2014. 20 However, we believe a larger number of cases arising from our ethnically diverse population with frequent international travel could have been identified. 21 Possible explanations for this discrepancy are healthcare barriers in our ethnically diverse and socially deprived population, 22 asymptomatic disease not requiring medical input, or mild disease misclassified by clinicians as another viral illness. The emergence of Zika virus as well as the re-emergence of Chikungunya virus and other arthropodborne viruses, make laboratory confirmation vitally important for epidemiological and clinical purposes. However, some clinicians might not actively pursue definitive laboratory confirmation of DF because it is not a notifiable disease in the UK. We observed a seasonal peak of imported DF during JulySeptember period but this is more likely to reflect increased travel during school summer holidays than seasonal variation of DENV transmission in endemic regions. 23 We also observed that most patients with viraemic DF presented during OctoberMarch compared to April-September but this apparent difference was not statistically significant. Unlike other imported arthropod-borne infections such as malaria, 24 little is known about the effect of season on the morbidity and mortality associated with imported DF. The GeoSentinel survey (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) showed that DF cases imported from Southeast Asia peaked during the June-September period during non-epidemic years but additional cases were reported on monthly basis during epidemics. 25 Furthermore, the Japanese dengue traveller surveillance (2006-14) showed a seasonal peak in DF cases imported from South and Southeast Asia during August-October period although the monthly distribution varied by countries within the same region. 26 Data from the EuroTravNet longitudinal surveillance revealed that the trends of imported DF generally mirrored that of other mosquito-borne infections. Some of our patients with imported DF had tropical coinfections, and this finding emphasizes the need for adopting a holistic approach when assessing febrile tropical travellers. HIV status was determined for only two thirds of our patients and this needs to be improved.
This study has several limitations. Data were retrospectively collected from patients' records and this can yield incomplete or absent data for some variables e.g. purpose of travel, previous vaccination against other flaviviruses. The small sample size did not provide us with sufficient power to construct a multivariate regression model and therefore we only managed to report age-adjusted ORs. Selection and recall biases are additional limitations to our study. Although this study was based at the largest healthcare provider in East London and its laboratory received DF referrals from primary and secondary care physicians, caution should be exercised when extrapolating these finding to other parts of the UK.
The global resurgence in DF and other arthropod-transmitted infections brings into sharp focus the need to scale-up integrated vector control activities in endemic countries as well as the need for educating travellers from non-endemic countries about the range of personal protective measures they can use. Clinicians need to improve DF recognition and laboratory confirmation as well as rates of HIV testing in travellers. Viraemic DF presentations are associated with travel to South and Southeast Asia as well as shorter time intervals between arriving from abroad and molecular testing. Further research on the clinical and public health aspects of imported DF is needed.
